Skip to content
HowShorted

Tonix Pharmaceuticals Holding short interest in 2025

In 2025, Tonix Pharmaceuticals Holding's disclosed short interest ran from 8.52% of shares outstanding on 15 Jan 2025 to 19.67% on 31 Dec 2025, a change of +11.15 percentage points. The year's high was 22.03% on 30 Sep 2025 and its low 5.21% on 31 Jan 2025, averaging 15.79% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.69 days on 31 Dec 2025. Full history: Tonix Pharmaceuticals Holding.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2025 · 2026

Aggregate net short position time series for Tonix Pharmaceuticals Holding in 2025

2025 in figures

Start of year
8.52% (15 Jan 2025)
End of year
19.67% (31 Dec 2025)
Change
+11.15 pp
High
22.03% (30 Sep 2025)
Low
5.21% (31 Jan 2025)
Average
15.79%
Highest days to cover
4.69 (31 Dec 2025)
SEC filings marked
12

Every report in 2025

Tonix Pharmaceuticals Holding short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20258.52%1.00
31 Jan 20255.21%1.00
31 Mar 202514.30%1.00results (8-K), 10-K filed, results (8-K)
15 Apr 202517.43%1.20
30 Apr 202515.17%1.67results (8-K)
15 May 202512.40%1.4310-Q filed, results (8-K)
30 May 202514.42%1.00
13 Jun 202515.42%1.47
30 Jun 202516.51%1.75
15 Jul 202516.23%1.50
31 Jul 202516.47%1.00results (8-K)
15 Aug 202515.37%1.0010-Q filed, results (8-K)
29 Aug 202513.39%1.00
15 Sep 202515.19%1.07
30 Sep 202522.03%1.63
15 Oct 202520.36%1.75
31 Oct 202520.93%2.78results (8-K)
14 Nov 202516.51%3.1210-Q filed, results (8-K)
28 Nov 202517.16%2.01
15 Dec 202518.83%4.03
31 Dec 202519.67%4.69

See also: Tonix Pharmaceuticals Holding's full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.